Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — President Biden on Friday will take aim at the pharmaceutical industry by ordering his administration to advance several vague policies that clearly take aim at drug makers: targeting high drug prices and importing drugs from Canada.

The new policies, which will be advanced via an executive order, are some of Biden’s first tangible steps on prescription drug pricing, an issue he has largely sidestepped so far in his presidency, or which has been mired in court delays. An official policy plan could send a clear signal about which Trump-era drug pricing policies this administration will keep, and which new ideas it will advance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment